首页 > 文献资料
-
内皮素与充血性心力衰竭
充血性心力衰竭(congestive heart failure,CHF)是各种病因心脏病终末阶段的主要临床表现,在CHF的进展中,不只有交感神经系统和肾素-血管紧张素(RAS)系统的活性亢进,还有内皮素系统的参与。……
-
倍他乐克治疗充血性心力衰竭的临床疗效分析
充血性心力衰竭(congestive heart failure,CHF)是指静脉回流正常的情况下,由于原发的心脏损害引起心排血量减少和心室充盈压升高,临床上以组织血液灌注不足以及肺循环和(或)体循环淤血为主要特征的一种临床综合征.其治疗在临床上是令人关注的重要课题之一.
-
卡维地洛治疗慢性充血性心力衰竭临床观察
近年来,受体阻滞剂在心力衰竭治疗药物方面已占有非常重要的地位.卡维地洛作为一种新型β受体阻滞剂,已应用于临床.本文通过对90例慢性充血性心力衰竭(chronic heart failure,CHF)患者的临床治疗对比观察,探讨国产卡维地洛治疗心力衰竭的临床疗效及安全性.
-
社会支持对少数民族慢性心力衰竭患者生活质量的影响
心力衰竭(Chronic Heart Failure,CHF)是一种复杂的临床征候群,是各种心脏疾病的严重阶段[1].由于人口老龄化以及高血压、冠心病存活时间延长,导致CHF患病率逐渐上升,尽管有了能够降低患者死亡率、延长生存期的药物,但10余年来心力衰竭患者的死亡率减少没有达到统计学显著性差异[2],现代医学模式认为人的寿命由生存的数量和生存的质量两个部分组成,提高生活质量与延长生存率、生存时间具有同样重要的意义.
-
中西医结合治疗慢性心力衰竭150例
1997~2000年,笔者自拟养心益肺汤结合西药治疗慢性顽固性心衰150例,疗效显著,现总结如下.
-
中医治疗慢性心力衰竭研究进展
慢性心力衰竭(chronic congestice heart failure)是以心悸、气促、肢体水肿为主症的一种病症[1],属于中医“心悸”、“心痹”、“喘证”、“水肿”、“怔忡”范畴[2]。近期内心衰的发病率将继续增长,正成为21世纪重要的心血管病症[3]。其防治已成为国内外研究的热点[4]。现将中医治疗慢性心力衰竭的研究综述如下。
-
Background: Infantile hepatic hemangioma (IHH) as a benign liver tumor in infancy and childhood is commonly associated with high output cardiac failure. The present study aims to describe the imaging findings in a patient who was diagnosed as having multiple IHH with congestive cardiac insuffi ciency.
Methods: The imaging findings and clinical manifestations of the patient with multiple IHH associated with cardiac insuffi ciency were retrospectively reviewed.
Results: Ultrasonography showed multiple intrahepatic lesions with mixed echoes and markedly expanded hepatic veins and the inferior vena cava of the patient. Echocardiography revealed right heart insufficiency and pulmonary hypertension. Contrast-enhanced MRI showed early mild enhancement of lesions and more obvious delayed enhancement. The patient died after combined therapy of surgery and hormone.
Conclusions: The imaging findings of multiple IHH associated with cardiac insufficiency are typical and diagnostic. Early imaging assessment may facilitate the diagnosis and treatment of the disease. -
Tumor necrosis factor-a (TNF-a) contributes to myocardial infarction (MI) injury. Polymorphism of TNF-a gene promoter region and secretion and release of TNF-a and its transformation by a series of signaling pathways are all changed at different points of pathophysiological process in MI. Researches also investigated TNF-a antagonists and their potential therapeutic role in the setting of MI and heart failure at both molecular and clinical level. This article briefly reviews TNF-a and its mechanism as a mediator in MI. Copyright ? 2015, Chinese Medical Association Production. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).